VanEck Associates’s Definium Therapeutics DFTX Stock Holding History

VanEck Associates’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.04M	Buy	+132,348	New	+$5.58M	﹤0.01%	839

Other funds holding DFTX

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Lord, Abbett & Co Jersey City, New Jersey $33.4B AUM 56.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

VanEck Associates's DFTX Position: Q3 2026 in Review

VanEck Associates opened a new position in Definium Therapeutics (DFTX) in Q3 2026: 132,348 shares worth $5.04M. The stake represents ﹤0.01% of the portfolio and ranks #839 among its holdings.

253 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

VanEck Associates held 132,348 shares of Definium Therapeutics worth $5.04M as of Q3 2026.
Definium Therapeutics was a new VanEck Associates position in Q3 2026.
Definium Therapeutics made up ﹤0.01% of VanEck Associates's portfolio in Q3 2026, its #839 holding.
253 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on VanEck Associates's 13F filing for Q3 2026, filed 13 Nov 2026.